Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.55 |
| ▸ | METAP1 | P53582 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 3/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16404333 | 0.91 | METAP1 (0.61) | CYP1B1CYP1A1CYP1A2ABCG2METAP1 | |
| SCHEMBL17275213 | 0.87 | METAP1 (0.57) | CYP1B1CYP1A1CYP1A2ABCG2METAP1 | |
| SCHEMBL25463096 | 0.87 | MEN1 (0.57) | CYP1B1CYP1A1CYP1A2ABCG2METAP1 | |
| SCHEMBL384799 | 0.87 | METAP1 (0.61) | ABCG2METAP1HTTMEN1KMT2A | |
| SCHEMBL29593068 | 0.86 | ATM (0.59) | CYP1B1CYP1A1CYP1A2ABCG2METAP1 | |
| SCHEMBL4847197 | 0.86 | ATM (0.59) | CYP1B1CYP1A1CYP1A2ABCG2METAP1 | |
| SCHEMBL13312483 | 0.83 | HTT (0.47) | CYP1B1CYP1A1CYP1A2ABCG2METAP1 | |
| SCHEMBL4840414 | 0.83 | ABCG2 (0.58) | CYP1A2ABCG2METAP1TP53MEN1 | |
| SCHEMBL31009730 | 0.83 | ABCG2 (0.58) | CYP1A2ABCG2METAP1TP53MEN1 | |
| SCHEMBL8240685 | 0.83 | ATM (0.65) | CYP1B1CYP1A1CYP1A2ABCG2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10032991-B2 | Compound, organic electroluminescence element material, ink composition, organic electroluminescence element, electronic device, and method for producing compound | IDEMITSU KOSAN CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20160197288-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC DEVICE, AND METHOD FOR PRODUCING COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160197288-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC DEVICE, AND METHOD FOR PRODUCING COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| WO-2006034512-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034491-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034512-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160197288-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC DEVICE, AND METHOD FOR PRODUCING COMPOUND | LEF1, L1CAM, OLA1 | CYP1B1 321/4885CYP1A1 230/4885CYP1A2 397/4885 |
| US-10032991-B2 | Compound, organic electroluminescence element material, ink composition, organic electroluminescence element, electronic device, and method for producing compound | LEF1, L1CAM, OLA1 | CYP1B1 321/4885CYP1A1 230/4885CYP1A2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.